185 related articles for article (PubMed ID: 25064743)
1. Outcomes of thalassemia patients undergoing hematopoietic stem cell transplantation by using a standard myeloablative versus a novel reduced-toxicity conditioning regimen according to a new risk stratification.
Anurathapan U; Pakakasama S; Mekjaruskul P; Sirachainan N; Songdej D; Chuansumrit A; Charoenkwan P; Jetsrisuparb A; Sanpakit K; Pongtanakul B; Rujkijyanont P; Meekaewkunchorn A; Sruamsiri R; Ungkanont A; Issaragrisil S; Andersson BS; Hongeng S
Biol Blood Marrow Transplant; 2014 Dec; 20(12):2066-71. PubMed ID: 25064743
[TBL] [Abstract][Full Text] [Related]
2. Risk adopted allogeneic hematopoietic stem cell transplantation using a reduced intensity regimen for children with thalassemia major.
Hussein AA; Al-Zaben A; Ghatasheh L; Natsheh A; Hammada T; Abdel-Rahman F; Abu-Jazar H; Sharma S; Najjar R; Frangoul H
Pediatr Blood Cancer; 2013 Aug; 60(8):1345-9. PubMed ID: 23424175
[TBL] [Abstract][Full Text] [Related]
3. A Comparison of the Myeloablative Conditioning Regimen Fludarabine/Busulfan with Cyclophosphamide/Total Body Irradiation, for Allogeneic Stem Cell Transplantation in the Modern Era: A Cohort Analysis.
Gooptu M; Kim HT; Ho VT; Alyea EP; Koreth J; Armand P; Ritz J; Nikiforow S; Glotzbecker BE; Nageshwar P; Soiffer RJ; Antin JH; Cutler CS
Biol Blood Marrow Transplant; 2018 Aug; 24(8):1733-1740. PubMed ID: 29555313
[TBL] [Abstract][Full Text] [Related]
4. New myeloablative conditioning regimen with fludarabine and busulfan for allogeneic stem cell transplantation: comparison with BuCy2.
Chae YS; Sohn SK; Kim JG; Cho YY; Moon JH; Shin HJ; Chung JS; Cho GJ; Yang DH; Lee JJ; Kim YK; Kim HJ
Bone Marrow Transplant; 2007 Sep; 40(6):541-7. PubMed ID: 17637692
[TBL] [Abstract][Full Text] [Related]
5. Pretransplant immunosuppression followed by reduced-toxicity conditioning and stem cell transplantation in high-risk thalassemia: a safe approach to disease control.
Anurathapan U; Pakakasama S; Rujkijyanont P; Sirachainan N; Songdej D; Chuansumrit A; Sirireung S; Charoenkwan P; Jetsrisuparb A; Issaragrisil S; Ungkanont A; Sruamsiri R; Srisala S; Andersson BS; Hongeng S
Biol Blood Marrow Transplant; 2013 Aug; 19(8):1259-62. PubMed ID: 23648235
[TBL] [Abstract][Full Text] [Related]
6. Busulfan-fludarabine- or treosulfan-fludarabine-based myeloablative conditioning for children with thalassemia major.
Lüftinger R; Zubarovskaya N; Galimard JE; Cseh A; Salzer E; Locatelli F; Algeri M; Yesilipek A; de la Fuente J; Isgrò A; Alseraihy A; Angelucci E; Smiers FJ; La La Nasa G; Zecca M; Fisgin T; Unal E; Kleinschmidt K; Peters C; Lankester A; Corbacioglu S;
Ann Hematol; 2022 Mar; 101(3):655-665. PubMed ID: 34999929
[TBL] [Abstract][Full Text] [Related]
7. Second Hematopoietic Stem Cell Transplant for Thalassemia Major: Improved Clinical Outcomes with a Treosulfan-Based Conditioning Regimen.
Korula A; Pn N; Devasia A; Lakshmi KM; Abraham A; Sindhuvi E; George B; Srivastava A; Mathews V
Biol Blood Marrow Transplant; 2018 Jan; 24(1):103-108. PubMed ID: 29032269
[TBL] [Abstract][Full Text] [Related]
8. Comparative effectiveness of busulfan/cyclophosphamide versus busulfan/fludarabine myeloablative conditioning for allogeneic hematopoietic cell transplantation in acute myeloid leukemia and myelodysplastic syndrome.
Patel SS; Rybicki L; Pohlman B; Bolwell B; Gerds AT; Hamilton BK; Hanna R; Kalaycio M; Majhail NS; Sobecks R
Hematol Oncol Stem Cell Ther; 2020 Sep; 13(3):160-165. PubMed ID: 31628924
[TBL] [Abstract][Full Text] [Related]
9. Treosulfan-thiotepa-fludarabine-based conditioning regimen for allogeneic transplantation in patients with thalassemia major: a single-center experience from north India.
Choudhary D; Sharma SK; Gupta N; Kharya G; Pavecha P; Handoo A; Setia R; Katewa S
Biol Blood Marrow Transplant; 2013 Mar; 19(3):492-5. PubMed ID: 23160007
[TBL] [Abstract][Full Text] [Related]
10. Comparison of Different Conditioning Regimens of Haploidentical Hematopoietic Stem Cell Transplant in Patients With Acute Myeloid Leukemia.
Jiang Y; Fang X; Sui X; Liu X; Li Y; Wang X; Xu H; Zhang L; Wang X
Exp Clin Transplant; 2018 Dec; 16(6):736-744. PubMed ID: 29790457
[TBL] [Abstract][Full Text] [Related]
11. Fludarabine-based reduced toxicity yet myeloablative conditioning is effective and safe particularly in patients with high-risk thalassemia undergoing allogeneic transplantation.
Sheth V; Grisariu S; Avni B; Stepensky P; Ashkenazi M; Shapira MY; Or R
Pediatr Blood Cancer; 2018 Nov; 65(11):e27312. PubMed ID: 30070020
[TBL] [Abstract][Full Text] [Related]
12. Comparison of pediatric allogeneic transplant outcomes using myeloablative busulfan with cyclophosphamide or fludarabine.
Harris AC; Boelens JJ; Ahn KW; Fei M; Abraham A; Artz A; Dvorak C; Frangoul H; Freytes C; Gale RP; Hong S; Lazarus HM; Loren A; Mineishi S; Nishihori T; O'Brien T; Williams K; Pasquini MC; Levine JE
Blood Adv; 2018 Jun; 2(11):1198-1206. PubMed ID: 29844205
[TBL] [Abstract][Full Text] [Related]
13. A Single-Center Experience Comparing Alemtuzumab, Fludarabine, and Melphalan Reduced-Intensity Conditioning with Myeloablative Busulfan, Cyclophosphamide, and Antithymocyte Globulin for Chronic Granulomatous Disease.
Khandelwal P; Bleesing JJ; Davies SM; Marsh RA
Biol Blood Marrow Transplant; 2016 Nov; 22(11):2011-2018. PubMed ID: 27543157
[TBL] [Abstract][Full Text] [Related]
14. Comparison of a fludarabine and melphalan combination-based reduced toxicity conditioning with myeloablative conditioning by radiation and/or busulfan in acute myeloid leukemia in Japanese children and adolescents.
Ishida H; Adachi S; Hasegawa D; Okamoto Y; Goto H; Inagaki J; Inoue M; Koh K; Yabe H; Kawa K; Kato K; Atsuta Y; Kudo K
Pediatr Blood Cancer; 2015 May; 62(5):883-9. PubMed ID: 25545836
[TBL] [Abstract][Full Text] [Related]
15. Unrelated Donor Peripheral Blood Stem Cell Transplantation for Patients with β-Thalassemia Major Based on a Novel Conditioning Regimen.
Sun L; Wang N; Chen Y; Tang L; Xing C; Lu N; Shi Y; Ma Y; Lin F; Yu K; Feng J
Biol Blood Marrow Transplant; 2019 Aug; 25(8):1592-1596. PubMed ID: 30951841
[TBL] [Abstract][Full Text] [Related]
16. Higher busulfan dose intensity does not improve outcomes of patients undergoing allogeneic haematopoietic cell transplantation following fludarabine, busulfan-based reduced toxicity conditioning.
Hamadani M; Craig M; Phillips GS; Abraham J; Tse W; Cumpston A; Gibson L; Remick SC; Bunner P; Leadmon S; Elder P; Hofmeister C; Penza S; Efebera Y; Andritsos L; Garzon R; Benson DM; Blum W; Devine SM
Hematol Oncol; 2011 Dec; 29(4):202-10. PubMed ID: 21360728
[TBL] [Abstract][Full Text] [Related]
17. Thiotepa, busulfan and fludarabine compared to busulfan and cyclophosphamide as conditioning regimen for allogeneic stem cell transplant from matched siblings and unrelated donors for acute myeloid leukemia.
Saraceni F; Beohou E; Labopin M; Arcese W; Bonifazi F; Stepensky P; Aljurf M; Bruno B; Pioltelli P; Passweg J; Sociè G; Santarone S; Yakoub-Agha I; Lanza F; Savani BN; Mohty M; Nagler A;
Am J Hematol; 2018 Oct; 93(10):1211-1219. PubMed ID: 30033639
[TBL] [Abstract][Full Text] [Related]
18. A comparison of immune reconstitution and graft-versus-host disease following myeloablative conditioning versus reduced toxicity conditioning and umbilical cord blood transplantation in paediatric recipients.
Geyer MB; Jacobson JS; Freedman J; George D; Moore V; van de Ven C; Satwani P; Bhatia M; Garvin JH; Bradley MB; Harrison L; Morris E; Della-Latta P; Schwartz J; Baxter-Lowe LA; Cairo MS
Br J Haematol; 2011 Oct; 155(2):218-34. PubMed ID: 21848882
[TBL] [Abstract][Full Text] [Related]
19. Outcomes following HSCT using fludarabine, busulfan, and thymoglobulin: a matched comparison to allogeneic transplants conditioned with busulfan and cyclophosphamide.
Bredeson CN; Zhang MJ; Agovi MA; Bacigalupo A; Bahlis NJ; Ballen K; Brown C; Chaudhry MA; Horowitz MM; Kurian S; Quinlan D; Muehlenbien CE; Russell JA; Savoie L; Rizzo JD; Stewart DA
Biol Blood Marrow Transplant; 2008 Sep; 14(9):993-1003. PubMed ID: 18721762
[TBL] [Abstract][Full Text] [Related]
20. Busulfan plus fludarabine as a myeloablative conditioning regimen compared with busulfan plus cyclophosphamide for acute myeloid leukemia in first complete remission undergoing allogeneic hematopoietic stem cell transplantation: a prospective and multicenter study.
Liu H; Zhai X; Song Z; Sun J; Xiao Y; Nie D; Zhang Y; Huang F; Zhou H; Fan Z; Tu S; Li Y; Guo X; Yu G; Liu Q
J Hematol Oncol; 2013 Feb; 6():15. PubMed ID: 23394705
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
